ADME Toxicology Testing Market Product Type, Segment by Regions and Scope Till 2026
ADME is an
abbreviation in pharmacokinetics and pharmacology, stands for
absorption, distribution, metabolism and elimination of chemicals and
drugs to define the impact in a human body. Toxicology testing is a
significant event before an introduction of new drugs into the
market. However, drug development is very crucial stage of the
pharmaceutical and biotechnology manufacturer as it is attributed to
high costs at the various stages of drug development. Thus, one of
the key factors linked to the last stage drug failure is due to
inability of new drug candidates to meet human and animal safety
profile. To overcome this barrier of drug failure, ADME toxicology
testing has a major advantage to enter in early drug development
phase of pre-clinical trials.
ADME toxicology
testing influence the drug levels and kinetics of drug exposure to
the body tissue and hence facilitated the performance in
pharmaceutical manufacturing by minimizing drug discovery time,
complications in testing and reduction in overall cost in drug
development. Thereby, pre-clinical ADME toxicology testing is a
substantial application in drug discovery venture capital (VC)
industries to make financial decisions in corresponds to significance
and scope in the drug discovery firms. Which is expected to gain more
traction of the ADME (absorption, distribution, metabolism and
elimination) toxicology testing market over the forecast period.
Request For
Sample Copy of This Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/1013
Global ADME
(Absorption, Distribution, Metabolism and Elimination) Toxicology
Testing Market Taxonomy:
On the basis on type
of product and technology, global ADME (absorption, distribution,
metabolism and elimination) toxicology testing market segmented into:
By product:
-
Instruments, Assay Systems, Software Solutions, Reagents, Others
By
Technology:
-
In-silico Testing, In-vitro Testing, In-vivo Testing
An effort
for early stage drug development by biopharmaceuticals and growing
demand for CRO’s advanced ADME toxicology testing is expected to
propel the ADME (absorption, distribution, metabolism and
elimination) toxicology testing market
In October, 2014,
Wuxi Pharma Tech announced that it has acquired Xenobiotic
Laboratories, Inc. (XBL) to aid its bioanalytical, drug metabolism
and pharmacokinetic (DMPK) and ADME (absorption, distribution,
metabolism and elimination) services for radio-labeled compounds.
Wuxi Pharma Tech’s intends in integrated service portfolio to
expand laboratory testing division in North America.
Furthermore, in
January, 2014, a specialist ADME-Tox Contract Research Organization
(CRO) - Cyprotex PLC entered into an acquisition agreement with an
initial financial value of US$ 0.73 million for the business and
assets of CeeTox, Inc. The Cyprotex intends to expand the portfolio
in in-vitro toxicity assays and screening services to the Cosmetics
and Personal Care Industry.
Evotec AG, who
offers drug research, development, and its manufacturing services to
pharmaceutical company, announced the completion of acquisition with
Cyprotex PLC in December, 2016. The deal was designed to enhance
Evotec’s ADME-Tox platform, in vitro ADME screening,
high-content toxicology screening and mechanistic and, predictive
modeling to strengthen its buyer’s drug discovery efforts for an
early stage drug development and this deal was closed in US$ 67.6
million. Thereby, is expected to stimulate the ADME (absorption,
distribution, metabolism and elimination) toxicology testing market
growth over the forecast period.
However, lack of
in-vitro models to detect autoimmunity and immune-stimulation may
hamper the market growth to some extent.
Increasing
demand for cell-based assay by bio-pharmaceutical company is expected
to boost the ADME (absorption, distribution, metabolism and
elimination) toxicology testing market
Growing adoption of
ADME toxicology testing by biotechnology and pharmaceuticals and
increasing demand for cell-based assays in drug discovery is major
driving factor fueling the ADME (absorption, distribution, metabolism
and elimination) toxicology testing market growth. For instance, in
September, 2017, a leading provider of bio specimens and its related
services, BioIVT has announced an acquisition agreement with Qualyst
Transporter Solutions, LLC. Qualyst’s cell-based testing approach
provides in vitro hepatic models and services which helps in the
prediction of the effect of drugs and other compounds in the human
liver. Thus, BioIVT enables to predict its new drug impact on the
liver. As ADME testing has proven to be an efficient time and cost
testing procedures.
Key player in ADME
(absorption, distribution, metabolism and elimination) toxicology
testing market include, Agilent Technologies, Inc., Cellartis AB,
Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Molecular
Discovery Ltd, Caliper Life Sciences, Inc., Cyprotex PLC, Optivia
Biotechnology, Inc., Promega Corporation and Beckman Coulter, Inc.
Click to read
more on ADME
Toxicology Testing Market
About Coherent
Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Comments
Post a Comment